Indeed, we found 9 out of 14 patients harbouring alterations in commonly mutated oncogenes, among which 5 had alterations in genes currently recommended for testing in NSCLC, as MET, ALK, EGFR and BRAF5,6,8–10. This evidence concerns the gene EGFR and non-small cell lung carcinoma.